Andrei Coliţă

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation

Andrei Coliţă, Anca Coliță, Horia Bumbea et al. · Frontiers in Oncology · 2019 · 30 citations · Full text

<i>MECOM</i>, <i>HBS1L‐MYB</i>, <i>THRB‐RARB, JAK2</i>, and <i>TERT</i> polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients

Adrian P. Trifa, Claudia Bănescu, Anca Bojan et al. · American Journal of Hematology · 2017 · 29 citations · Full text

Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: A retrospective study of 54 cases

Andrei Coliţă, A Belhabri, Youcef Chelghoum et al. · Annals of Oncology · 2001 · 21 citations

Prognostic Factors, Hematological Malignancy, Medicine +12

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases

Letiția-Elena Radu, Andrei Coliţă, Sergiu Paşca et al. · Frontiers in Oncology · 2020 · 21 citations · Full text